Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
Author(s): Deniz A. Ucar, Andrew T. Magis, Di-Hua He, Nicholas J. Lawrence, Said M. Sebti, Elena Kurenova, Maria Zajac-Kaye, Jianliang Zhang, Steven N. Hochwald	Department of Surgical Oncology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
Volume 13 , Issue 4 , 2013
DOI : 10.2174/1871520611313040009
Pancreatic cancer is one of the most lethal diseases with no effective treatment. Previously, we have shown that FAK is overexpressed in pancreatic cancer and plays a key role in cancer cell survival and proliferation. FAK has been shown to interact with growth factor receptors including cMET and IGF-1R. As a novel therapeutic approach, we targeted the protein interaction of FAK with growth factor receptors to block tumor growth, alter signaling pathways and sensitize cells to chemotherapy. We have selected a small molecule compound (INT2-31) that decreases phosphorylation of AKT via disrupting interaction of FAK with cMET and IGF-1R. Our results demonstrate that interaction of a small molecule compound with FAK decreases phosphorylation of FAK Y397 while increasing FAK Y407 phosphorylation, without inhibiting the kinase activity of FAK and dramatically reduces downstream signaling to AKT. Our lead compound, INT2-31, demonstrates significant inhibition of tumor cell growth in two orthotopic models of pancreatic cancer. In addition, INT2-31increases sensitivity to gemcitabine chemotherapy in a direct fresh biopsy xenograft model of pancreatic cancer growth.
Keywords: FAK, IGF-1R, Pancreatic cancer, Protein interactions
Title:Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
VOLUME: 13	ISSUE: 4
Author(s):Deniz A. Ucar, Andrew T. Magis, Di-Hua He, Nicholas J. Lawrence, Said M. Sebti, Elena Kurenova, Maria Zajac-Kaye, Jianliang Zhang and Steven N. Hochwald
Affiliation:Department of Surgical Oncology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
Keywords:FAK, IGF-1R, Pancreatic cancer, Protein interactions
Abstract:Pancreatic cancer is one of the most lethal diseases with no effective treatment. Previously, we have shown that FAK is overexpressed in pancreatic cancer and plays a key role in cancer cell survival and proliferation. FAK has been shown to interact with growth factor receptors including cMET and IGF-1R. As a novel therapeutic approach, we targeted the protein interaction of FAK with growth factor receptors to block tumor growth, alter signaling pathways and sensitize cells to chemotherapy. We have selected a small molecule compound (INT2-31) that decreases phosphorylation of AKT via disrupting interaction of FAK with cMET and IGF-1R. Our results demonstrate that interaction of a small molecule compound with FAK decreases phosphorylation of FAK Y397 while increasing FAK Y407 phosphorylation, without inhibiting the kinase activity of FAK and dramatically reduces downstream signaling to AKT. Our lead compound, INT2-31, demonstrates significant inhibition of tumor cell growth in two orthotopic models of pancreatic cancer. In addition, INT2-31increases sensitivity to gemcitabine chemotherapy in a direct fresh biopsy xenograft model of pancreatic cancer growth.
Deniz A. Ucar, Andrew T. Magis, Di-Hua He, Nicholas J. Lawrence, Said M. Sebti, Elena Kurenova, Maria Zajac-Kaye, Jianliang Zhang and Steven N. Hochwald, "Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo", Anti-Cancer Agents in Medicinal Chemistry (2013) 13: 595. https://doi.org/10.2174/1871520611313040009
https://doi.org/10.2174/1871520611313040009 Print ISSN
Published on: 07 March, 2013
Ligand-Based Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on Substituted Thiazoles and Thiophenes as Polo-Like Kinase 1 (Plk1) Inhibitors
Combinatorial Chemistry & High Throughput Screening
Preclinical Analyses of the Therapeutic Potential of Allopregnanolone to Promote Neurogenesis In Vitro and In Vivo in Transgenic Mouse Model of Alzheimers Disease
Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics
Anticancer Potential of Thiazole Derivatives: A Retrospective Review
Mini-Reviews in Medicinal Chemistry
Role of Azoles in Cancer Prevention and Treatment: Present and Future Perspectives
Mitochondria-Targeting Anticancer Metal Complexes
Molecular Imaging: Translation from Rats to Dogs and Humans
Current Medical Imaging
Using Protein-protein Interaction Network Information to Predict the Subcellular Locations of Proteins in Budding Yeast
Protein & Peptide Letters
The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to any Systematic Therapy: A Systematic Review
Current Stem Cell Research & Therapy
FAK and Nanog Cross Talk with p53 in Cancer Stem Cells
Hijacking the Hedgehog Pathway in Cancer Therapy
Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy
Breast Cancer: Current Molecular Therapeutic Targets and New Players
Chemotherapeutic Targeting of Cell Death Pathways
The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Inhibitors of Cancer Stem Cells
Lauric Acid Modulates Cancer-Associated microRNA Expression and Inhibits the Growth of the Cancer Cell
Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug- Resistant Cells
Palladium (II) Complex Enhances ROS-Dependent Apoptotic Effects via Autophagy Inhibition and Disruption of Multiple Signaling Pathways in Colorectal Cancer Cells